SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is surging following FDA approval of Bysanti (milsaperidone) for bipolar I disorder and schizophrenia, with the community anticipating a major valuation re-rating and potential buyout due to its blockbuster market potential alongside the company's Tradipitant pipeline targeting GLP-1 induced nausea.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending following a sector-wide sell-off driven by fears that Anthropic's new Claude Code Security tool will disrupt traditional cybersecurity, sparking intense community debate over CRWD's valuation versus its distinct role in endpoint and cloud protection against evolving AI threats.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as community discussion focuses on its strategic exclusion from China's national drug list, aiming to preserve pricing power, while investors keenly await a pending U.S. Supreme Court decision on its patent infringement case. This coincides with anticipated positive financial results and ongoing speculation about a potential acquisition as the company positions for a turnaround.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is a hot topic as reports of halted redemptions from one of its private credit funds and challenges in financing a CoreWeave data center fuel widespread fears of liquidity issues in the broader private credit sector. Management maintains they are accelerating capital returns and all projects remain fully funded, leading to sharp community debate on the company's true financial health.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space (FJET) is driving significant investor conversation and high volatility as its team rings the NYSE Opening Bell, following successful wind tunnel testing for its STARLAUNCH I rocket. The community is intensely debating its potential for a short squeeze and its role in the expanding space and defense sectors ahead of next week's NYSE Space Summit, with many anticipating further upward movement.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics (KYTX) is trending following positive Phase 2 data for its miv-cel CAR-T therapy in Stiff Person Syndrome, meeting all primary and secondary endpoints and supporting a future BLA filing. The community highlights the therapy's groundbreaking potential in autoimmune diseases, robust cash runway, and significant analyst price target increases, fueling strong long-term optimism amidst recent stock fluctuations.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is trending after strong earnings and an upgraded growth outlook fueled analyst upgrades, though many in the community debate if its rapid expansion justifies the current high valuation amidst broader restaurant sector concerns.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending following its Q4 earnings beat and expanding AI integrations, though conservative guidance and a broader software sector re-evaluation are driving a significant sell-off that has reversed initial gains. The community is split between acknowledging Datadog's critical role in cloud observability and questioning the severity of its valuation reset amidst generalized AI-driven market fear.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending due to robust demand for AI infrastructure and surging memory chip prices, which are propelling its major holdings like TSM and MU. While many investors see it as a strong play, others in the community view its rapid, 'parabolic' ascent as an 'AI bubble' poised for correction amidst overvaluation concerns.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as a bullish Citron Research report highlights its leadership in autonomous AI agent security through its Prompt Security acquisition, sparking debate among investors frustrated by its perceived undervaluation. The community emphasizes the company's strong, debt-free fundamentals and recent government contract authorizations, arguing its AI-native solutions are crucial against escalating cyber threats and signaling potential for a significant rebound or acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>If implemented, this change would transition from a mix of local jails and privately operated prisons to a centralized model featuring larger facilities, as per the Bloomberg report.&nbsp;</li><li>A reduction in ICE's network may significantly impact a key revenue source for GEO Group and CoreCivic, who collectively hold about 58% of individuals detained by ICE.</li><li>In 2025, GEO entered into new contracts to house ICE detainees at four facilities totaling approximately 6,000 beds.</li></ul>Shares of GEO Group and CoreCivic fell on Friday on report that Immigration and Customs Enforcement (ICE) is planning to shrink down its network of privately owned detention facilities.Immigration and Customs Enforcement reportedly intends to reduce its network of over 200 detention centers—primarily run by private companies—to only 34 government-owned locations, a change that would impact established private prison corporations such as GEO Group and CoreCivic Inc.If implemented, this change would transition from a mix of local jails and privately operated prisons to a centralized model featuring larger facilities—mainly industrial warehouses—owned by the Department of Homeland Security, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-19/trump-s-immigration-push-to-warehouses-could-cut-out-corecivic-geogroup">report</a> from Bloomberg News, citing local officials briefed on the plan.<h2 class="st-heading-2">Hit On GEO Group And CoreCivic</h2>A reduction in ICE's network may significantly impact a key revenue source for GEO Group and CoreCivic, who collectively hold about 58% of individuals detained by ICE, as per the report that cited company disclosures.Contracts from ICE account for nearly half of GEO’s projected revenue of $2.9 billion to $3.1 billion for 2026. For CoreCivic, the revenues from ICE accounted for 40% of its entire fourth quarter revenue.&nbsp;In December 2025, GEO Group was awarded a new two-year contract by ICE for the provision of Skip Tracing services. In 2025, GEO entered into new contracts to house ICE detainees at four facilities totaling approximately 6,000 beds, increasing ICE capacity from approximately 20,000 beds to approximately 26,000 beds.&nbsp;ICE will now rely primarily on government-owned facilities but private companies will maintain a role, which may include providing services such as medical care and security, Bloomberg said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GEO and CXW trended in ‘bullish’ territory.&nbsp;Shares in GEO and CXW have fallen 52% and 12%, respectively.&nbsp; &nbsp;

 A view of the CoreCivic Otay Mesa Detention Center in San Diego, California, United States on February 07, 2025. 

GEO Group And CoreCivic Stocks Are Getting Beaten Up Today – Why Such A Selloff?

 Immigration and Customs Enforcement reportedly plans to shrink its network of more than 200 detention facilities, according to a Bloomberg News report. 

Equity

 Immigration and Customs Enforcement reportedly plans to shrink its network of more than 200 detention facilities, according to a Bloomberg News report. 


<ul class="summary-bullets"><li>SRx Health Solutions had first announced a stake in Opendoor in Jan. 2026.</li><li>Lennar Corporation also reported taking a significant position in Opendoor Technologies, as per a filing on Wednesday.&nbsp;</li><li>On Thursday, Opendoor Technologies posted Q4 revenue of $736 million, beating street expectations of $591.75 million.</li></ul>SRx Health Solutions, Inc. (SRXH) announced on Friday that it is increasing its ownership in Opendoor Technologies Inc. (OPEN) by 30% even as the real estate digital platform’s shares soar amid strong fourth-quarter (Q4) results.SRx Health Solutions had first announced a stake in Opendoor in January this year, calling the investment a part of its broader capital allocation strategy in segments that it viewed as “undervalued” and offering “attractive risk-adjusted return” potential.The health and wellness company added that it has further reduced its short position across its cryptocurrency portfolio of Bitcoin and Ethereum, and is now net long its holdings.Meanwhile, Opendoor Technologies extended its upward climb on Friday after its Q4 revenues beat Wall Street expectations. Shares of OPEN were up 12% at the time of writing.Shares of SRXH were down more than 1%.<h2 class="st-heading-2">Other Bullish Positions</h2>Lennar Corporation, one of the largest homebuilders in the U.S., also reported taking a significant position in Opendoor Technologies, as per a filing on Wednesday. The homebuilder said it would be holding 18.8 million shares along with multiple warrant series.Bank of America also reportedly raised its stake in Opendoor, while Vanguard Group disclosed an ownership interest of over 11% last month.<h2 class="st-heading-2">Opendoor’s Quarterly Results</h2>On Thursday, Opendoor Technologies posted <a href="https://stocktwits.com/news-articles/markets/equity/open-shares-soar-after-hours-on-q4-beat/cZRkaSYR4DW">Q4 revenue</a> of $736 million, about 36% lower than the same quarter in the previous year. However, it beat street expectations of $591.75 million, as per data from Fiscal.ai.Opendoor reported that its acquisitions grew 46% quarter-over-quarter, and inventory days in possession dropped 23%. The company also said that its Oct. 2025 acquisition cohort, the first whole month under its new Opendoor 2.0 model, is set to generate the strongest contribution margins of any October cohort in the company’s history.<h2 class="st-heading-2">Ḫow Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OPEN/">OPEN shares</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volumes climbed from ‘high’ to ‘extremely high’ levels.Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/SRXH">SRXH shares</a> dropped to ‘bullish’ from ‘extremely bullish’ over the past 24 hours, amid ‘high’ message volumes.Shares of OPEN have risen more than 245% in the past year, while shares of SRXH have plummeted more than 93% in the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-trnr-stock-plummet-today/cZRNIZqR4xi">Why Did TRNR Stock Plummet 32% Today?</a>

In this photo illustration, the Opendoor logo is seen displayed on a mobile phone screen.

OPEN Stock Attracts Bigger Bet From SRx Health Solutions Amid Strong Q4 Results

SRx Health Solutions announced on Friday that it is increasing its ownership in Opendoor Technologies by 30%.

<ul class="summary-bullets"><li>Hourly workers on the manufacturing, logistics, and quality teams are not affected by the cuts, the report said.&nbsp;</li><li>Based on Lucid’s report of 6,800 full-time employees as of Dec. 31, 2024, the layoff is likely to impact roughly 800 employees.</li><li>The layoffs come amidst the company’s efforts to ramp up deliveries of its Gravity SUV, and launch a new lower-cost midsize vehicle.</li></ul>EV maker Lucid Motors (LCID) is reportedly laying off 12% of its workforce as it gears up to profitability amid efforts to ramp deliveries of its Gravity SUV.Techcrunch <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://techcrunch.com/2026/02/20/lucid-motors-slashes-12-of-its-workforce-as-it-seeks-profitability/">reported</a> on Friday, citing an internal memo, that the layoffs are likely to impact hundreds of employees. Hourly workers on the manufacturing, logistics, and quality teams are not affected by the cuts, the report said.Based on Lucid’s report of 6,800 full-time employees as of Dec. 31, 2024, the layoff is likely to impact roughly 800 employees. A majority of the company’s workers are based at the company’s headquarters in California and its regional headquarters in Riyadh, Saudi Arabia, in addition to its manufacturing facilities in Casa Grande, Arizona, and Saudi Arabia, the company had said in its 2024 annual report.<h2 class="st-heading-2">CEO Speaks</h2>“We are grateful for the contributions of those impacted by today’s actions, and we are providing severance, bonus, continued health benefits, and transition support to help them through this period,” interim CEO Marc Winterhoff reportedly wrote in the internal memo sent to employees not involved in the workforce reduction action.The CEO also added that the company’s core priorities remain the same, including the start of production of the company’s midsize platform.The company is expected to announce its fourth quarter and full-year earnings on Feb. 24.<h2 class="st-heading-2">Lucid Attempts To Ramp Deliveries</h2>The layoffs come amidst the company’s efforts to <a href="https://stocktwits.com/news-articles/markets/equity/lucid-hits-highest-delivery-numbers-in-q4-while-rivals-rivian-tesla-witness-demand-drop/cmxMsCZR4Rd">ramp up deliveries</a> of its Gravity SUV, and launch a new lower-cost midsize vehicle.The company sold 15,841 vehicles in 2025, marking a growth of 55% year-on-year. The company currently sells two vehicles, including the Air sedan and the newer Gravity SUV. Both the vehicles cater to a more premium audience, owing to their higher price points.The company is looking to start the production of a midsize platform later this year with the aim of expanding into the mass-market EV segment. Lucid is looking to launch three vehicles on the platform, starting with a midsize crossover priced around $50,000.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LCID stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/LCID">LCID stock</a> has dropped 71% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-clears-key-us-antitrust-review-pursuit-of-warner-bros-discovery/cZRN93sR4xj">Paramount Clears Key US Antitrust Review In $77.9 Billion Pursuit Of Warner Bros. Discovery</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The 2025 Lucid Gravity electric sports utility vehicle (SUV) is displayed during the 2023 Los Angeles Auto Show at the Los Angeles Convention Center. (Photo by Josh Lefkowitz/Getty Images)

Lucid Reportedly Lays Off 12% Workforce Amid Gravity SUV Ramp-Up 

Techcrunch reported on Friday, citing an internal memo, that the layoffs are likely to impact hundreds of employees.

<ul class="summary-bullets"><li>Meanwhile, the company’s loss per share came in at $1.26, trailing market expectations of loss per share of $0.11.&nbsp;</li><li>Opendoor said that its acquisitions increased 46% quarter-over-quarter, while inventory days in possession reduced 23%.&nbsp;</li><li>The company said that it expects Q1 revenue to decrease approximately 10% quarter-over-quarter.</li></ul>Shares of Opendoor Technologies Inc. (OPEN) rallied more than 16% in after-market hours on Thursday after the company beat earnings expectations by a significant margin.The real estate digital platform posted revenue for the fourth-quarter (Q4) of $736 million, much above street expectations of $591.75 million, as per data from Fiscal.ai. Meanwhile, the company’s loss per share came in at $1.26, trailing market expectations of a loss per share of $0.11.The company also reported adjusted earnings before interest, tax, depreciation, and amortization of -$43 million, compared with an expectation of -$50.81 million.Opendoor said that it expects Q1 revenue to decrease approximately 10% quarter-over-quarter.<h2 class="st-heading-2">Progress Details</h2>Opendoor said that its acquisitions increased 46% quarter-over-quarter, while inventory days in possession reduced 23%.The company also noted that its October 2025 acquisition cohort, the first full month under the Opendoor 2.0 model, is on track to generate the strongest contribution margins of any October cohort in its history.These homes are also selling more than twice as fast as those acquired in October 2024, the company said, with over half already sold or under contract.“These results reflect structural improvements in how we operate with more accurate pricing, faster inventory turns, and disciplined selection,” said Kaz Nejatian, CEO of Opendoor.While newer cohorts remain in early stages, current performance is encouraging and underpins the company’s Q1 2026 contribution margin outlook, Nejatian added.<h2 class="st-heading-2">Bullish Bets</h2>New <a href="https://stocktwits.com/news-articles/markets/equity/open-stock-rallies-ahead-of-q4-report-after-lennar-bet-can-results-hold-the-gains/cZRjr3mR4wZ">filings</a> on Wednesday revealed that Lennar Corporation, one of the largest homebuilders in the U.S., has taken a significant position in the online real estate platform, holding 18.8 million shares along with multiple warrant series, signaling a strong bullish stance.Bank of America also reportedly raised its stake in the company, while Vanguard Group disclosed an ownership interest of over 11% last month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OPEN">OPEN shares</a> jumped to ‘extremely bullish’ from ‘bullish’ territory over the past 24 hours amid ‘high’ message volumes.Shares of the company have gained more than 200% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Opendoor Technologies (Open Door) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OPEN Shares Soar After-Hours On Q4 Revenue Beat, Higher Acquisitions

The real estate digital platform posted revenue for the fourth-quarter (Q4) of $736 million, much above street expectations of $591.75 million, as per data from Fiscal.ai. 

<ul class="summary-bullets"><li>As part of the deal, Accord will utilize more than 100 sales, medical, and marketing professionals to drive the adoption of Anktiva in the U.K., the European Union, Norway, Iceland, and Liechtenstein.</li><li>ImmunityBio founder Patrick Soon-Shiong said the company’s goal is to expand access to Anktiva by completing a randomized trial in patients with BCG-naïve disease.</li><li>The company announced on Wednesday that it has received EU approval for the use of Anktiva in combination with BCG.</li></ul>ImmunityBio Inc. (IBRX) on Thursday announced a partnership with Accord Healthcare to expand access to Anktiva across 30 countries.The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio shares</a> were down around 9% in Thursday’s opening trade after surging about 42% on Wednesday. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">ImmunityBio’s Partnership With Accord</h2>ImmunityBio said its partnership with Accord will help it unlock the full commercial potential of Anktiva in Europe.“Our partnership with Accord marks a significant step in our European growth strategy and our mission to redefine cancer care,” said ImmunityBio CEO Richard Adcock.As part of the deal, Accord will utilize more than 100 sales, medical, and marketing professionals to drive the adoption of Anktiva in the United Kingdom, the European Union, Norway, Iceland, and Liechtenstein.ImmunityBio founder Patrick Soon-Shiong said that the company’s goal is to broaden access to Anktiva by completing the randomized trial in patients with BCG-naïve disease, which refers to non-muscle invasive bladder cancer (NMIBC) in patients who have never received Bacillus Calmette-Guérin (BCG) immunotherapy, or those who experience recurrence more than 24 months after completing prior BCG treatment.<h2 class="st-heading-2">ImmunityBio Receives EU Approval</h2>ImmunityBio&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-gains-on-fresh-approval-for-bladder-cancer-drug-in-eu/cZR0UjXR4vV">announced</a> on Wednesday that it has received EU approval for the use of Anktiva in combination with BCG.This comes days after the Saudi Food and Drug Authority (SFDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/how-high-can-ibrx-stock-go-after-saudi-fda-bladder-cancer-nod/cZR0i4ZR4H1">encouraged</a> the company to submit a regulatory filing for its recombinant BCG therapy to help address treatment shortages and expand access.The company also said that it is in talks with Saudi regulators to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-jumps-pre-market-saudi-update-bcg/cZRWmDaR4uh">broaden</a> Anktiva’s use in combination with checkpoint inhibitors across multiple tumor types. Last month, the SFDA granted ImmunityBio accelerated approval for Anktiva in the treatment of metastatic non-small cell lung cancer and for BCG-unresponsive bladder cancer.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is up 306% year-to-date and 106% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-jobless-claims-report-february-14-2026-week/cZRj6UmR4DT">Jobless Claims Drop By Most In Over Two Months, Coming In Below Expectations</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries

The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.

<ul class="summary-bullets"><li>Lemonade noted that while its growth drivers are increasingly diversified, insurance for pets and cars remains in the driver’s seat.</li><li>The company’s pet insurance segment delivered an IFP growth in the mid-50s for the second consecutive year, accounting for a total of $439 million during the year.</li><li>The car insurance segment also delivered a notable IFP growth of 53% during the year, accounting for $187 million of Lemonade’s total In Force Premiums.</li></ul>Lemonade Inc. (LMND) shares soared nearly 18% in Thursday’s pre-market trade after the company reported its ninth consecutive quarter of In Force Premium (IFP) growth acceleration.“The strength of Q4's results reflects the compounding nature of our model. Faster growth expands our data advantage, which sharpens our AI-powered segmentation and pricing models,” Lemonade said, while noting that IFP grew 31% year-on-year to $1.24 billion in Q4.Lemonade’s fourth-quarter (Q4) results also beat Wall Street estimates. The company reported a loss of $0.29 per share during the quarter on revenue of $228 million, while Wall Street analysts expected a loss of $0.39 per share on revenue of $218 million, according to Stocktwits data.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/LMND">Lemonade</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘high’ levels.<h2 class="st-heading-2">Pets And Cars Drive Lemonade’s Growth</h2>Lemonade noted that while its growth drivers are increasingly diversified, insurance for pets and cars remains in the driver’s seat.Lemonade’s pet insurance segment delivered an IFP growth in the mid-50s for the second consecutive year, accounting for a total of $439 million during the year. “Our share of new pet insurance business continued to expand: Lemonade now has the fastest-growing share of Google search volume among U.S. pet insurance companies,” the company said.The car insurance segment also delivered a notable IFP growth of 53% during the year, accounting for $187 million of the company’s total In Force Premiums. Lemonade expects 2026 to be the year of a broader breakout for car insurance.The segment also showed a significant underwriting improvement, with loss ratio improving meaningfully as pricing segmentation, telematics-driven loss prediction, claims efficiency, and accuracy all advanced in parallel, Lemonade added.<h2 class="st-heading-2">AI Drives Down Lemonade’s Cost Of Claims</h2>The New York-headquartered insurance company also noted that artificial intelligence has driven down its cost of claims.Lemonade Pets, for instance, saw a continued decline in the cost of claims during 2025. The company said that while each pet insurance claim cost $44 in 2021, it is now down to $14.“Our 2025 result of $14 represents a level we believe to be industry-leading and is a clear testament to the growing impact of AI across claims and operations,” Lemonade said.<h2 class="st-heading-2">2026 Outlook</h2>For fiscal year 2026, Lemonade sees revenue in the $1.187 billion to $1.192 billion range, compared to a consensus estimate of $1.16 billion. In the first quarter (Q1), Lemonade expects revenue to be between $246 million and $251 million, compared to an estimated $241.57 million, according to TheFly.“We will continue to deploy our LTV AI across channels, products, and geographies to drive rapid gross profit growth, while using AI to drive operating leverage and reach Adjusted EBITDA profitability,” the company added.<a href="https://stocktwits.com/symbol/LMND">LMND stock</a> is down 8% year-to-date, but up 71% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iaea-chief-warns-iran-not-much-time-left-as-trump-warns-of-consequences/cZRjHiQR4wt">IAEA Chief Warns Iran 'Not Much Time' Left For Nuclear Deal As Trump Signals Consequences: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

​​In this photo illustration, the Lemonade logo is displayed on a smartphone screen on Feb. 23, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

LMND Stock Soars Pre-Market: Lemonade Extends Premium Growth Streak To Ninth Consecutive Quarter

Lemonade reported a 31% year-on-year growth in In Force Premium to $1.24 billion in the fourth quarter.

<ul class="summary-bullets"><li>Opendoor is expected to post quarterly revenues of $594.02 million, based on seven analyst estimates, according to data from Fiscal.ai.&nbsp;</li><li>Analysts expect the company to post a loss per share of $0.11, lower than the loss per share of $0.16 posted in the same period last year.&nbsp;</li><li>In Dec. 2025, the company named Lucas Matheson as President and Christy Schwartz as the CFO.</li></ul>Opendoor Technologies Inc. (OPEN) was in the retail spotlight on Wednesday, ahead of its fourth-quarter (Q4) 2025 earnings that are expected after-hours on Feb. 19.On Stocktwits, retail chatter around <a href="https://stocktwits.com/symbol/OPEN">OPEN stock</a> increased 336% in 24 hours, according to data from Wednesday morning, rising from ‘low’ to ‘normal’ levels.Meanwhile, retail sentiment around the shares of the company jumped from ‘bearish’ to ‘bullish’ territory over the past day.<h2 class="st-heading-2">Q4 Expectations</h2>The real estate digital platform will post its first results under the new chief executive officer, Kaz Nejatian, a former Shopify executive, who took over the reins of the company from former CEO Carrie Wheeler as of Sept. 2025.Opendoor is expected to post quarterly revenues of $594.02 million, based on seven analyst estimates, according to data from Fiscal.ai. This is almost 45% lower than revenues of $1.1 billion posted in the same period last year, as the company navigates a severely cooled housing market and high interest rates.Meanwhile, analysts on Fiscal.ai expect the company to post a loss per share of $0.11, lower than the loss per share of $0.16 it posted in the same period last year.<h2 class="st-heading-2">Recent Leadership Overhaul</h2>In Dec. 2025, the company announced major leadership changes in a bid to accelerate its next growth phase. Opendoor named Lucas Matheson as President of the company.Matheson had previously been CEO of Coinbase Canada and had also spent five years at Shopify. Meanwhile, Christy Schwartz, who had previously served as the interim Chief Financial Officer, took over as the CFO on Jan. 1, 2026."My job is to find the best person for every seat," said Nejatian about the appointments. "This is the team for the next version of Opendoor, one built for speed, clarity, and impact. Every day we don't make real progress is a day we don't make homeownership better. We're not going to waste days."<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>One bullish user on Stocktwits reiterated their positive outlook, saying the company’s shares would go up after earnings on ‘some good news.’<stembedurl>https://stocktwits.com/GGofCA/message/645187652</stembedurl>&nbsp;However, another bearish user predicted bad earnings that would push OPEN shares to $2.50. Shares of the company were trading at $4.61 at the time of writing.<stembedurl>https://stocktwits.com/JMandInvestments/message/645142489</stembedurl>&nbsp;OPEN stock has gained more than 191% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/what-is-sending-snap-shares-up-today/cZR0CYCR4vt">What’s Sending SNAP Shares Up Today?</a>

OPEN Stock Garners Retail Attention Ahead Of Q4 Results — What Are Analysts Expecting?

Opendoor Technologies will report its fourth-quarter (Q4) 2025 earnings after-hours on Feb. 19. 

<ul class="summary-bullets"><li>Nelson Peltz, founder of Trian Fund Management, holds a 16.24% stake in Wendy's, according to a filing.</li><li>The filing further said that Peltz could “enter into financial instruments or other agreements” with other parties to “increase or decrease” his economic exposure on that investment.&nbsp;</li><li>Peltz’s Trian Fund Management has spoken with potential financing sources, potential co-investors and certain potential strategic partners.</li></ul>Activist investor Nelson Peltz said that he is reviewing alternatives with regards to his investment in Wendy’s, as the founder of investment firm Trian Fund Management holds 16.24% stake in Wendy's, according to a filing.Shares jumped more than 14% at the time of writing.&nbsp;Peltz’s Trian Fund Management has spoken with potential financing sources, potential co-investors and certain potential strategic partners, regarding potential transactions in which such parties could participate and may benefit the company's shareholders, according to the regulatory filing.&nbsp;Peltz thinks that Wendy's stock is undervalued and said that he is considering his options that potentially involve buying more shares of the company or selling all or part of his stake.&nbsp;The filing further said that Peltz could “enter into financial instruments or other agreements” with other parties to “increase or decrease” his economic exposure on that investment.&nbsp;Peltz had considered a similar move back in 2022 but decided not to go ahead with it and opted for higher dividend and corporate restructuring. He resigned as chairman of Wendy’s board in 2024 to devote more time to his hedge fund.&nbsp;<h2 class="st-heading-2">Weak Forecast</h2>Wendy’s last week forecasted weak guidance for FY2026 that disappointed investors. The fast-food chain’s 2026 profit outlook of $0.56 to $0.60 per share fell well short of analyst expectations of $0.85 and at the time triggered selloff in the stock.&nbsp;Wendy’s fourth quarter profit of $0.16 per share scraped past analysts’ earnings of $0.15 per share. Its revenue of $543 million in the quarter also edged above analysts’ estimates of $537.5 million.&nbsp;Its global sales fell 8.3% to $3.4 billion in the quarter along with same-restaurant sales falling 10.1% globally.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WEN trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 45% over the past year.&nbsp; &nbsp;

A Wendy’s outlet in Bloomsburg, Pennsylvania, United States. 

Wendy’s Stock Jumps As Nelson Peltz Says He Is Reviewing His Investment 

Peltz thinks that Wendy's stock is undervalued and that he is considering his options that potentially involve buying more shares of the company or selling all or part of his stake. 

<ul class="summary-bullets"><li>Starboard said it is intending to nominate a highly-qualified slate of directors representing a majority of the Board.&nbsp;</li><li>Tripadvisor said its management and the Board are focused on pursuing all avenues to drive value for shareholders.</li></ul>Shares of TRIP rallied on Tuesday after it responded to a shareholder letter from Starboard value who has urged Tripadvisor to either explore sale or shake up its board.&nbsp;At the time of writing, TRIP stock was 6.5% up.&nbsp;<h2 class="st-heading-2">Starboard Value’s Letter</h2>Starboard said that it believes that Tripadvisor should be formally exploring a sale of the entire company, in one or multiple transactions. Starboard holds more than 9% stake in the company.&nbsp;Starboard in its letter to TRIP highlighted the company’s prolonged underperformance and failure to take decisive action to create shareholder value.&nbsp;“Shareholders deserve a credible, comprehensive process focused on maximizing value. If this Board cannot take decisive action in a timely manner, as it has proven time and time again, we believe it is time for meaningful change,” it said in a shareholder letter.&nbsp;&nbsp;“We have offered to work with Tripadvisor to reconstitute the Board, but it has become clear to us that we must take action into our own hands and seek to replace a majority of the Board,”&nbsp;Starboard&nbsp;added.&nbsp;Starboard said that during TripAdvisor’s upcoming window for shareholders to submit director nominations with respect to its 2026 annual meeting of shareholders, Starboard is intending to nominate a highly-qualified slate of directors representing a majority of the Board.&nbsp;<h2 class="st-heading-2">TRIP’s Response</h2>Tripadvisor said that its Board and management team regularly engage with investors and welcome constructive input that furthers the common goal of enhancing value for all shareholders.Tripadvisor will continue to take actions it believes will drive sustainable value as it executes its strategic priorities and further positions the company for long-term growth, it said in a response to the shareholder letter.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around TRIP trended in ‘neutral’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have risen 42% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a Tripadvisor logo is seen displayed on a smartphone. 

Why Is TRIP Stock Rallying Today?

 Starboard said that it believes that Tripadvisor should be formally exploring a sale of the entire company, in one or multiple transactions.

<ul class="summary-bullets"><li>ImmunityBio began discussions with SFDA to expand the use of ANKTIVA in combination with checkpoint inhibitors for multiple tumor types.</li><li>ANKTIVA is already approved in Saudi Arabia for two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic lung cancer.</li><li>Earlier this year, ImmunityBio established a wholly owned local subsidiary to support regulatory filings, commercialization, and clinical development.</li></ul>Shares of ImmunityBio, Inc. (IBRX) climbed about 6% in premarket trading on Tuesday after the Saudi Food and Drug Authority (SFDA) encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin (rBCG), a move aimed at expanding treatment access in Saudi Arabia and easing the ongoing global shortage.&nbsp;The company said it expects to file the submission within the next few weeks. BCG is an immunotherapy drug used to treat early-stage bladder cancer.&nbsp;<h2 class="st-heading-2">Expanding ANKTIVA Across Tumor Types</h2>The company also began discussions with the SFDA to broaden the use of ANKTIVA in combination with checkpoint inhibitors for multiple tumor types beyond metastatic non-small cell lung cancer. ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune protein that helps develop and activate key cells that destroy cancer cells.The therapy <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-gain-retail-attention-today/cmULjP5R4eA">received</a> accelerated approval in Saudi Arabia in January 2026 for patients whose disease progressed after standard treatments. Data from the QUILT-3.055 Phase 2b trial showed the combination restored checkpoint inhibitor activity across cancers such as melanoma, renal, gastric, and cervical tumors, with a median overall survival of 14.1 months in relapsed lung cancer patients.<h2 class="st-heading-2">Strengthening Regional Presence</h2>ANKTIVA is already approved in Saudi Arabia for two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic lung cancer. ImmunityBio has also established a wholly owned local subsidiary to support regulatory filings, commercialization, and clinical development across the Middle East and North Africa.“Saudi Arabia was the first country in the world to grant approval for ANKTIVA in metastatic lung cancer. The QUILT-3.055 basket trial provides data that ANKTIVA rescues checkpoint activity across multiple tumor types, and we look forward to working with the SFDA to extend this approach to additional malignancies,” said Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.Soon-Shiong <a href="https://stocktwits.com/news-articles/markets/equity/anktiva-vs-keytruda-immunity-bio-exec-chair-slams-fda-for-double-standards-in-approvals/cZRW7FaR4M8">recently criticized</a> the U.S. Food and Drug Administration (FDA), claiming the agency accelerated approval for Merck &amp; Co.’s cancer therapy Keytruda while limiting ANKTIVA to a single bladder cancer indication.Speaking on The Roger Stone Show, Soon-Shiong argued that regulatory delays are creating a bottleneck that could restrict patient access to a treatment he believes has significant life-saving potential.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the premarket movement, retail sentiment for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> on Stocktwits remained ‘bearish’ over the past 24 hours.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_242ebbcbd6.webp" alt="IBRX.jpg">However, chatter was more bullish, with one user looking to buy more shares because the ‘price is attractive.’<stembedurl>https://stocktwits.com/Deggie/message/645099523</stembedurl>Another user expects a strong rebound following a slight dip at market open.<stembedurl>https://stocktwits.com/Wowsuchboolish/message/645100328</stembedurl>The stock has seen strong buying interest so far this year, gaining more than 210%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gold-silver-prices-fall-peter-schiff-buy-the-dips/cZRWkdSR4ua">Peter Schiff&nbsp;Signals ‘Buy The Dips’ As Gold, Silver Extend Fall – PAAS, AG, HL Stocks Down Over 3.5% Premarket</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’

The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.

Current Price	$279.14
Prev Close	$278.19
Open	$277.32
Dividend Yield	N/A
50-Day Moving Average	$269.26
Beta	N/A
Avg. Volume	780,624.60
PE Ratio	N/A

52-Week High	$281.47
52-Week Low	$190.27
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

VB
Vanguard Small Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VB News

VBVanguard Small Cap ETF